IPSC compared with SRZN: revenue, margins and what each company keeps, and the suppliers and customers both name

IPSCCentury Therapeutics, Inc.

Mkt capRevenueRevenue

SRZNSurrozen, Inc.

Mkt capRevenueRevenue

Compare

IPSCCentury Therapeutics, Inc.

SRZNSurrozen, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

IPSC1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±29.8%▼−4.85%×0.16

SRZN2 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Oct 21 '26±19.1%▲+0.72%×0.04

Q2 FY26—▲+18.39%—

= impliedIPSC realized, solidSRZN realized, hatchedOne scale, both sides: full bar = 30%× = |realized| ÷ impliedSource: market data

IPSCCentury Therapeutics, Inc.

1.70▲+12.33%· post 1.70

Mkt cap$304.2MRevenue$109MQ1 FY25Revenue$7MFY24

SRZNSurrozen, Inc.

30.97▲+6.80%· post 30.98

ClosedNov 6 '26

Mkt cap$717.5MRevenue$5MQ2 FY26Revenue$3MFY25

Compare

ClosedNov 6 '26

IPSCCentury Therapeutics, Inc.

SRZNSurrozen, Inc.

1.70▲+12.33%post 1.70

Price

30.97▲+6.80%post 30.98

$304.2M

Mkt cap

$717.5M

Q1 FY25$109M

Revenue

$5MQ2 FY26

FY24$7M

Revenue

$3MFY25

IPSC1.70▲+12.33%vsSRZN30.97▲+6.80%ClosedNov 6 '26